Home » News » CROs/Service Providers » Covance Revenue Up 8% in ‘09, Plans for 10% Growth in ‘10

Covance Revenue Up 8% in ‘09, Plans for 10% Growth in ‘10

Thursday, January 28, 2010

Covance reported fourth-quarter revenue growth of 11% to $507 million, largely due to the positive impact of foreign exchange.

The CRO’s revenues grew 8% in 2009. Year-end revenues were $1.96 billion in 2009 compared with $1.83 billion in 2008. Operating margin was 11.3%.  Earnings per share were $2.73 for the year and $0.64 per diluted share for the fourth quarter.

Covance expects full-year revenue growth in 2010 to be 10% over 2009, and earnings per share to be in the range of $2.50 to $2.75.

Covance’s late-stage business, including central laboratory, phase II and III clinical development and commercialization services, jumped 26% in the fourth quarter to $282 million. Full-year net revenues grew 22% to $1.1 billion compared to $883.3 million in 2008.  

The company’s early-development segment did not fare as well, with revenues down 5% to $203 million from the fourth quarter last year.  Full year net revenues in this segment declined 6% to $792 million compared with $845 million in 2008.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!